Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

Recruiting now

Conditions studied: ESCC

In brief

Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability to detect early-stage lesions. To address this clinical need, the SYNERGY study seeks to develop a non-invasive, blood-based biomarker assay that integrates cell-free microRNAs (cf-miRNAs) and exosomal microRNAs (exo-miRNAs) to detect ESCC at an early and potentially curable stage. This multicenter translational study includes discovery, training, and validation phases using preoperative plasma or serum samples. By combining the tumor specificity of exosomal miRNAs with the systemic sensitivity of cf-miRNAs, SYNERGY aims to construct a robust diagnostic model with high sensitivity and specificity for early ESCC detection.

Key facts

Study ID

NCT07266363

Run by

City of Hope Medical Center

People needed

600

Starts

2025-01-15

Expected to finish

2028-06-18

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults age 18 to 90 years
• Histologically confirmed esophageal squamous cell carcinoma
• No prior systemic therapy before sample collection
• For control groups: absence of malignant disease

You may not qualify if…

• Lack of informed consent
• Inadequate sample volume or RNA quality
• Prior cancer within 5 years (except localized cancers)
• Active systemic inflammation that may alter circulating RNA profiles

Where it is running

• City of Hope Medical Center — Monrovia, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.